Empagliflozin and its impact on hepatic and metabolic outcomes in patients with type 2 diabetes and NAFLD: a systematic review and meta-analysis
Empagliflozin improves liver fat, stiffness, glycemic control, body weight, and uric acid in T2DM with MASLD, but its effects on fibrosis and inflammation remain uncertain. Larger, long-term histologic trials are needed to confirm these outcomes.
Authors
- Ashna Habib (ORCID: https://orcid.org/0000-0001-5421-0212)
- Muhsin Aboud (ORCID: https://orcid.org/0009-0003-5341-4258)
- Zarwa Rashid (ORCID: https://orcid.org/0000-0003-4876-5726)
- Yousif Hameed Kurmasha
- Mohammedsadeq A. Shweliya (ORCID: https://orcid.org/0009-0000-2832-6270)
- Abanoub I.I. Kamel
- Mayar Moghazy
- Fatima Fahem
- Aya Ahmed Shimal
- Marafi Jammaa Ahmed
- Ali Saad Al-Shammari
- Abdulhadi M. A. Mahgoub
- Ahmed Elgazzar
- Khadeeja Ali Hamzah
Institutions
- Latakia University (SY)
- Kafrelsheikh University (EG)
- University of Baghdad (IQ)
- King Edward Medical University (PK)
- Dow University of Health Sciences (PK)
- Ark Medical Center (US)
- University of Al-Qadisiyah (IQ)
- University of Bahri (SD)
- University of Kufa (IQ)
- University of Gezira (SD)
- Minia University (EG)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1186/s13098-025-02084-x
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00